Drugs / 11C-PBR28
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02233868 | Feb 2015 → Aug 2021 | alcohol-related disorders | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT04490096 | Feb 2021 → Mar 2022 | amyotrophic lateral sclerosis | University of Pennsylvania | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03705715 | May 2017 → Aug 2028 expected | psychiatric disorder | The University of Texas Health Science Center, Houston | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01547780 | Jan 2012 → Sep 2017 | traumatic brain injury | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05661903 | Jun 2023 → Aug 2027 expected | chronic pain syndrome | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT02831283 | Jun 2016 → Dec 2022 | Alzheimer disease | Patrick Lao | Completed | No outcome recorded |
| Phase 2 | NCT02702102 | Dec 2015 → Sep 2019 | Lewy body dementia, Parkinson disease | Columbia University | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04230174 | Dec 2020 → Oct 2024 | multiple sclerosis | Massachusetts General Hospital | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | \[11C\]PBR28 | “Using magnetic resonance-PET (MR-PET) imaging with \[11C\]PBR28, a second-generation 18kDa translocator protein (TSPO) radiotracer, we have previously demonstrated abnormally...” NCT04230174 ↗8“The use of \[11C\]PBR28 will allow us to assess for the first time in vivo if there is neuroinflammation in the brain of alcoholics.” NCT02233868 ↗ “This imaging involves administration of the \[11C\]PBR28 radioligand, which is an investigational drug.” NCT05661903 ↗ |
| Known as | PBR28 | “Recently, our laboratory developed PBR28, a new PET ligand that images TSPO with high levels of specific binding.” NCT01547780 ↗ |
| Modality | Diagnostic / imaging agent | “11C\]PBR28 is a new PET ligand that images TSPO with high levels of specific binding.” NCT01547780 ↗ |
| Route | Intravenous | “Single intravenous injection of \[C-11\]PBR28, \~10-20 mCi” NCT01547780 ↗ |
| Target | TSPO | “Translocator protein 18 kDa (TSPO) has been widely imaged as a marker of neuroinflammation using several radioligands, including [11C]PBR28.” PMID 29749279 ↗ May 2018 |